On January 22, 2026, Cowen & Co. maintained its Buy recommendation on Johnson & Johnson, simultaneously raising its price target from 222 to 250. This upward revision reflects Cowen’s confidence in J&J’s near‐term growth trajectory, driven primarily by the company’s leading positions in immunology and oncology franchises. While the firm retains a Hold stance on the stock’s current valuation, the elevated target underscores expectations for continued operational leverage and margin expansion over the next 12–18 months.

Zacks Investment Research has identified J&J as a top medical stock candidate to exceed consensus earnings estimates, citing its proprietary Earnings ESP model. This tool highlights instances where recent analyst revisions have turned more positive than negative, suggesting a greater likelihood of upside surprises. Analysts at Zacks point to robust demand for Darzalex and Stelara as key drivers that could propel fourth‐quarter and full‐year results above street forecasts.

With a market capitalization approaching 530 billion, J&J ranks among the largest healthcare companies globally. Trading volume has averaged over 2.2 million shares daily in recent sessions, indicating sustained liquidity and institutional interest. The company’s valuation metrics remain supportive relative to peers in pharmaceuticals and medical devices, reinforcing its status as a core holding in many large‐cap portfolios.

Johnson & Johnson’s diversified portfolio—spanning medical devices, pharmaceuticals and consumer health—provides multiple avenues for growth. Upcoming product launches in neuroscience and cardiovascular interventions, combined with a disciplined M&A pipeline, are expected to drive revenue growth north of 6% in fiscal 2026. The maintained Buy rating and higher price target from Cowen, along with positive signals from Zacks, collectively strengthen J&J’s appeal as a defensive yet growth‐oriented healthcare investment.